Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18227188 | 0.90 | LMNA (0.55) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL1813593 | 0.88 | NPC1 (0.51) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL9470658 | 0.85 | SYK (0.51) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL16460026 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL7306620 | 0.85 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL10498167 | 0.85 | GAA (0.49) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL8891764 | 0.82 | ALDH1A1 (0.59) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11388818 | 0.82 | ALDH1A1 (0.58) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL234454 | 0.81 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL1920842 | 0.80 | L3MBTL1 (0.56) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894390-B1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RES GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-12378196-B2 | Synthesis of (S)-6-hydroxytryptophan and derivatives thereof | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-08-05 | — | — | US | disclosed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| EP-4499636-A2 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| CN-113166057-B | Synthesis of (S) -6-hydroxytryptophan and derivatives thereof | 海德堡医药研究有限责任公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1054000-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYSTEINE DERIVATIVES | KANEKA CORPORATION (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-6150388-A | Indole derivatives as 5-HT1 agonists | PFIZER, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6011170-A | SULFIDING A PROTECTED CYSTEINE DERIVATIVE WITH A MERCAPTAN WHEREIN THE REACTION IS CONDUCTED IN THE PRESENCE OF A BASE AND WATER IN AN ORGANIC REACTION SOLVENT. | KANEKA CORPORATION (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0897911-A1 | PROCESS FOR PRODUCING CYSTEINE DERIVATIVES | KANEKA CORPORATION (JP) | 1999-02-24 | — | — | EP | disclosed |
| CN-1190390-A | Nitric oxide synthase inhibitors derived from cyclic amidines | SEARLE & CO (US) | 1998-08-12 | — | — | CN | disclosed |
| US-5747501-A | Indole derivatives | PFIZER, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0635017-A1 | INDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993020073-A1 | INDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER INC. (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | SMN1; SMN2 2214/4885LMNA 3184/4885ALDH1A1 1992/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | SMN1; SMN2 2065/4885LMNA 743/4885ALDH1A1 2302/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SMN1; SMN2 3214/4885LMNA 3817/4885ALDH1A1 1658/4885 |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | AANAT, HNMT, HTR6 | SMN1; SMN2 4294/4885LMNA 3591/4885ALDH1A1 2998/4885 |
| US-12378196-B2 | Synthesis of (S)-6-hydroxytryptophan and derivatives thereof | AANAT, HNMT, HTR6 | SMN1; SMN2 4312/4885LMNA 3706/4885ALDH1A1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.